BSR/BHPR DMARD Guidelines

Total Page:16

File Type:pdf, Size:1020Kb

BSR/BHPR DMARD Guidelines Rheumatology 2008; 1 of 16 doi:10.1093/rheumatology/kel216b Guidelines BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists K. Chakravarty, H. McDonald1, T. Pullar2, A. Taggart3, R. Chalmers4, S. Oliver5,6, J. Mooney7, M. Somerville8, A. Bosworth9, T. Kennedy10 on behalf of the British Society for Rheumatology, British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group in consultation with the British Association of Dermatologists KEY WORDS: DMARD, Guideline, Multidisciplinary, Multi professional. Scope and purpose effects can be significant in some patients. Most specialists recommend regular safety monitoring of these drugs based on Background to disease/the drug therapy clinical experience and the data from published literature, such as Inflammatory arthritis, and especially rheumatoid arthritis (RA), Product Specific Characteristics, the British National Formulary is common and affects over 1% of the population. Even in the (BNF) and publications from various clinical trials in the specialty 21st century, the prognosis of RA remains uncertain. It runs a literature [3–6]. The adverse effects of DMARDs as reported in variable and unpredictable course. Several longitudinal studies research trials have limitations, as the patient characteristics are have demonstrated the progressive course of the disease, leading likely to be different from those in daily clinical practice. It is to joint destruction and deformity and, ultimately, to loss of desirable if not necessary, to have some form of guideline which is functional independence and to residual disability. Research has multidisciplinary with patient participation, using evidence base, shown that early intervention with disease specific anti-rheumatic peer reviewed, well researched and supported by some study/audit drugs, also called second line drugs or disease-modifying anti- of national practice. In 2000 the British Society for Rheumatology rheumatic drugs (DMARDs) is the cornerstone of treatment and, (BSR) produced its second edition of DMARD monitoring in the early stages may be able to curb or arrest the progressive guidelines for rheumatologists but this was considered by the synovitis and joint destruction and thereby limit disability [1]. committee for evaluation of guidelines of the Royal College of This guideline is intended to help clinicians and allied health Physicians to be more appropriate as a ‘practical tool’ than professionals, both in primary and secondary care, to make guideline. The need for a review of the guideline is, therefore, not decisions about DMARD therapy, with particular reference to only timely but also of paramount importance as the approach their toxicity profile. These drugs are used in a number of to therapy of many rheumatological and dermatological diseases conditions, including RA, psoriasis and psoriatic arthritis, as well has changed in the recent years, with greater accumulation of as the connective tissue diseases and vasculitis. It is essential that evidence since the last publication. Moreover, the current DMARDs are used in appropriate doses to achieve an optimal DMARD guideline has been developed in collaboration with balance between benefit and risk [2]. the British Association of Dermatologists (BAD), as there is a common interest to prevent and limit toxicity associated with the use of these drugs in these two specialties. Need for guideline The use of DMARDs in rheumatology and dermatology requires the use of guidelines for drug toxicity monitoring, as adverse Objective of the guideline This guideline provides a list of licensed and unlicensed indica- Harold Wood Hospital, BHR Trust, Romford, 1Gubbins Lane Surgery, Harold tions for the use of DMARDs in rheumatology and dermatology. Wood, 2Ninewells Hospital, Dundee, 3Musgrave Park Hospital, Belfast, It provides an evidence-based approach with appropriate refer- 4Manchester Royal Infirmary, Manchester, 5Royal College of Nursing ences to all recommendations in terms of predicting, assessing and Rheumatology Forum, London, 6Litchdon Health Centre, Barnstaple, 7Norfolk & counteracting any toxic effects related to the use of the DMARDs Norwich University Hospital and University of East Anglia, 8Norfolk & Norwich in these two specialties. University Hospital, Norwich, 9National Rheumatoid Arthritis Society, Maidenhead The main objective of this guideline is to provide clear 10 and Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, UK. information that the responsible clinician can use to ensure Submitted 19 February 2006; revised version accepted 11 March 2008. DMARDs may be safely prescribed and monitored. Correspondence to: K. Chakravarty, Harold Wood Hospital, BHR NHS Trust, It is expected that the guidelines should be viewed with Romford, Essex, RM7 OBE, UK. E-mail: [email protected] individual drug SPC’s (Summary of Product Characteristics) 1of16 ß The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: [email protected] 2of16 K. Chakravarty et al. and together will provide sufficient up-to-date knowledge about Dr Harry McDonald Royal College of General the DMARDs. This guideline also addresses many unresolved and General Practitioner Practitioners evolving issues that can be considered as part of a research or Gubbins Lane Surgery audit, locally or nationally. Havering PCT It is essential that clinicians remember to report (yellow card Essex system) any serious adverse events (SAE) related to the use of DMARDs. Dr Tom Kennedy BSR–Consultant Royal Liverpool and Broadgreen Rheumatologist University Hospital Trust Target audience Prescott Road This document is targeted at the following: Liverpool (1) Health care professionals in primary and secondary care. Mrs Janice Mooney Specialist Nurse (2) Health service managers. Lecturer/Practitioner (Rheumatology Forum) (3) Patients receiving these drugs and patient organizations, Norfolk & Norwich such as Arthritis Care, and national patient support groups, University Hospital such as the National Rheumatoid Arthritis Society (NRAS). Norwich (4) Other national societies, such as the BAD. Mrs Susan Oliver Royal College of Nursing Nurse Consultant & Chairperson, The areas the guideline does not cover Rheumatology Forum Royal College of Nursing (1) The management of DMARD therapy in children with London inflammatory arthritis. The British Society for Paediatric and Adolescent Rheumatology (BSPAR) has produced Dr Tom Pullar BSR–Consultant guidelines [7]. Consultant Rheumatologist Rheumatologist (2) The management of the underlying disease for which the Ninewells Hospital DMARD is prescribed. Dundee (3) The management of RA with immunotherapies, such as anti-TNF, anti-IL-1 and anti-B-cell therapy [8]. Ms Margaret Somerville BHPR (British Health (4) This guideline does not advise specific monitoring profile for Clinical Research Manager Professionals in patients receiving ‘combination’ therapy. Where the mon- Norfolk & Norwich Rheumatology) itoring schedule is different between the drugs used in University Hospital combination, it is advised to adopt a more stringent Norwich monitoring schedule based on clinical judgement. (5) This guideline does not advise on the management of Dr Allister Taggart BSR–Consultant patients on cyclophosphamide, as this drug is more Consultant Rheumatologist Rheumatologist commonly used in the treatment of vasculitis and will be Musgrave Park Hospital discussed in the guideline for the management of adults with Belfast vasculitis [9]. (6) Immunization: It is beyond the scope of this guideline to Names and affiliations of users on the working group give detailed advice on immunization in patients treated Mrs Ailsa Bosworth with DMARDs, as there is insufficient evidence about the Chief Executive, NRAS degree of immunosuppression induced by the drugs. National Rheumatoid Arthritis Society (NRAS) However, some general principles have been mentioned. Unit B4, Westcott Business Centre The advice on immunization, particularly against encapsu- Westcott Way, Little Wick Green lated organism, such as pneumovax, has been mentioned Maidenhead, SL6 3RT on the website of the Health Protection Agency. As guidelines are evolving, in difficult cases it is advisable to discuss with the Health Protection Agency, or check their Involvement of other people or organizations including user website, for further advice (Prof. Liz Miller, Centre for representative organizations and pharmaceutical companies Infectious Disease and Immunisation, Colindale, London, in the development of the guideline personal communication). This guideline was developed in collaboration with the NRAS. Patient surveys related to DMARD treatments and the patients’ Stakeholder involvements perspectives have been included [10]. No representatives of phar- maceutical companies were involved in guideline development. Names and roles of members of multidisciplinary team Names Representing Rigour of development Prof. Kuntal Chakravarty BSR–Chairman Statement of scope of literature search and strategy Consultant Rheumatologist employed BHR Trust Hospitals Harold Wood Hospital A comprehensive literature search was undertaken prior to the Romford, Essex development of this guideline. Searches were conducted using MEDLINE, CINAHL, Cochrane, PUBMED, EMBASE, AMED Dr Robert Chalmers British
Recommended publications
  • Us 8530498 B1 3
    USOO853 0498B1 (12) UnitedO States Patent (10) Patent No.: US 8,530,498 B1 Zeldis (45) Date of Patent: *Sep. 10, 2013 (54) METHODS FORTREATING MULTIPLE 5,639,476 A 6/1997 OShlack et al. MYELOMAWITH 5,674,533 A 10, 1997 Santus et al. 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL- 395 A 22 N. 2-YL)PIPERIDINE-2,6-DIONE 5,731,325 A 3/1998 Andrulis, Jr. et al. 5,733,566 A 3, 1998 Lewis (71) Applicant: Celgene Corporation, Summit, NJ (US) 5,798.368 A 8, 1998 Muller et al. 5,874.448 A 2f1999 Muller et al. (72) Inventor: Jerome B. Zeldis, Princeton, NJ (US) 5,877,200 A 3, 1999 Muller 5,929,117 A 7/1999 Muller et al. 5,955,476 A 9, 1999 Muller et al. (73) Assignee: Celgene Corporation, Summit, NJ (US) 6,020,358 A 2/2000 Muller et al. - 6,071,948 A 6/2000 D'Amato (*) Notice: Subject to any disclaimer, the term of this 6,114,355 A 9, 2000 D'Amato patent is extended or adjusted under 35 SS f 1939. All et al. U.S.C. 154(b) by 0 days. 6,235,756 B1 5/2001 D'Amatoreen et al. This patent is Subject to a terminal dis- 6,281.230 B1 8/2001 Muller et al. claimer 6,316,471 B1 1 1/2001 Muller et al. 6,326,388 B1 12/2001 Man et al. 6,335,349 B1 1/2002 Muller et al. (21) Appl. No.: 13/858,708 6,380.239 B1 4/2002 Muller et al.
    [Show full text]
  • Multinational Evaluation of Mycophenolic Acid, Tacrolimus
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE providedORIGINAL by University of QueenslandPAPER eSpace ISSN 1425-9524 © Ann Transplant, 2016; 21: 1-11 DOI: 10.12659/AOT.895664 Received: 2015.08.15 Accepted: 2015.09.01 Multinational Evaluation of Mycophenolic Published: 2016.01.05 Acid, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus Utilization Authors’ Contribution: ABCDEF Kyle M. Gardiner School of Pharmacy, University of Queensland, Brisbane, QLD, Australia Study Design A ACDEF Susan E. Tett Data Collection B Statistical Analysis C ACDEF Christine E. Staatz Data Interpretation D Manuscript Preparation E Literature Search F Funds Collection G Corresponding Author: Christine E. Staatz, e-mail: [email protected] Source of support: Departmental funding only Background: Increasing immunosuppressant utilization and expenditure is a worldwide challenge as more people success- fully live with transplanted organs. Our aims were to characterize utilization of mycophenolate, tacrolimus, cy- closporin, sirolimus, and everolimus in Australian transplant recipients from 2007 to 2013; to identify specific patterns of usage; and to compare Australian utilization with Norwegian, Danish, Swedish, and the Netherlands use. Material/Methods: Australian utilization and expenditure data were captured through national Pharmaceutical Benefits Scheme and Highly Specialized Drug administrative databases. Norwegian, Danish, Swedish, and the Netherlands uti- lization were retrieved from their healthcare databases. Utilization was compared as defined daily dose per 1000 population per day (DDD/1000 population/day). Data on kidney transplant recipients, the predominant patient group prescribed these medicines, were obtained from international transplant registries. Results: From 2007–2013 Australian utilization of mycophenolic acid, tacrolimus and everolimus increased 2.7-fold, 2.2- fold, and 2.3-fold, respectively.
    [Show full text]
  • WHO Drug Information Vol 22, No
    WHO Drug Information Vol 22, No. 1, 2008 World Health Organization WHO Drug Information Contents Challenges in Biotherapeutics Miglustat: withdrawal by manufacturer 21 Regulatory pathways for biosimilar Voluntary withdrawal of clobutinol cough products 3 syrup 22 Pharmacovigilance Focus Current Topics WHO Programme for International Drug Proposed harmonized requirements: Monitoring: annual meeting 6 licensing vaccines in the Americas 23 Sixteen types of counterfeit artesunate Safety and Efficacy Issues circulating in South-east Asia 24 Eastern Mediterranean Ministers tackle Recall of heparin products extended 10 high medicines prices 24 Contaminated heparin products recalled 10 DacartTM development terminated and LapdapTM recalled 11 ATC/DDD Classification Varenicline and suicide attempts 11 ATC/DDD Classification (temporary) 26 Norelgestromin-ethynil estradiol: infarction ATC/DDD Classification (final) 28 and thromboembolism 12 Emerging cardiovascular concerns with Consultation Document rosiglitazone 12 Disclosure of transdermal patches 13 International Pharmacopoeia Statement on safety of HPV vaccine 13 Cycloserine 30 IVIG: myocardial infarction, stroke and Cycloserine capsules 33 thrombosis 14 Erythropoietins: lower haemoglobin levels 15 Recent Publications, Erythropoietin-stimulating agents 15 Pregabalin: hypersensitivity reactions 16 Information and Events Cefepime: increased mortality? 16 Assessing the quality of herbal medicines: Mycophenolic acid: pregnancy loss and contaminants and residues 36 congenital malformation 17 Launch
    [Show full text]
  • Patient Focused Disease State and Assistance Programs
    Patient Focused Disease State and Assistance Programs Medication Medication Toll-free Brand (Generic) Website number Additional Resources Allergy/Asthma Xolair (omalizumab) xolair.com 1-866-4-XOLAIR lung.org Cardiovascular Pradaxa (dabigatran) pradaxa.com 877-481-5332 heart.org Praluent (alirocumab) praluent.com 844-PRALUENT thefhfoundation.org Repatha (evolocumab) repatha.com 844-REPATHA Tikosyn (dofetilide) tikosyn.com 800-879-3477 Crohn’s Disease Cimzia (certolizumab pegol) cimzia.com 866-4-CIMZIA crohnsandcolitis.com Humira (adalimumab) humira.com 800-4-HUMIRA crohnsforum.com Stelara (ustekinumab) stelarainfo.com 877-STELARA Dermatology Cosentyx (secukinumab) cosentyx.com 844-COSENTYX psoriasis.org Dupixent (dupilumab) dupixent.com 844-DUPIXENT nationaleczema.org Enbrel (etanercept) enbrel.com 888-4-ENBREL Humira (adalimumab) humira.com 800-4-HUMIRA Otezla (apremilast) otezla.com 844-4-OTEZLA Stelara (ustekinumab) stelarainfo.com 877-STELARA Taltz (ixekizumab) taltz.com 800-545-5979 Hematology Aranesp (darbepoetin alfa) aranesp.com 805-447-1000 chemocare.com Granix (filgrastim) granixrx.com 888-4-TEVARX hematology.org Jadenu (deferasirox) jadenu.com 888-282-7630 Neulasta (pegfilgrastim) neulasta.com 800-77-AMGEN Neupogen (filgrastim) neupogen.com 800-77-AMGEN Nivestym (filgrastim) nivestym.com 800-879-3477 Zarxio (filgrastim) zarxio.com 800-525-8747 Zytiga (abiraterone) zytiga.com 800-JANSSEN Hepatitis B Baraclude (entecavir) baraclude.com 800-321-1335 cdc.gov Viread (tenofovir disoproxil viread.com 800-GILEAD-5 hepb.org fumarate)
    [Show full text]
  • Hpra Drug Safety 66Th Newsletter Edition
    FEBRUARY 2015 HPRA DRUG SAFETY 66TH NEWSLETTER EDITION 3 Mycophenolate mofetil (CellCept) and 4 Direct Healthcare Professional In this Edition Mycophenolic acid (Myfortic) - New warnings Communications published on about the risks of hypogammaglobulinaemia the HPRA website since the last 1 Eligard (leuprorelin acetate depot injection) and bronchiectasis Drug Safety Newsletter - Risk of lack of efficacy due to incorrect reconstitution and administration process 4 Tecfidera (dimethyl fumarate) - Progressive Multifocal Leukoencephalopathy (PML) has 2 Beta interferons – Risk of thrombotic occurred in a patient with severe microangiopathy and nephrotic syndrome and prolonged lymphopenia Eligard (leuprorelin acetate depot injection) - Risk of lack of efficacy due to incorrect reconstitution and administration process Following identification of a signal and safe treatment of patients with It is available in six-monthly (45mg), of administration errors with Eligard prostate cancer. Lack of efficacy may three-monthly (22.5mg) and one- and concerns that such errors may occur due to incorrect reconstitution monthly (7.5mg) formulations. In impact on clinical efficacy, this issue of Eligard. the majority of patients, androgen was reviewed at EU level by the deprivation therapy (ADT) with Eligard Eligard is indicated for the treatment Pharmacovigilance Risk Assessment results in testosterone levels below the of hormone dependent advanced Committee (PRAC). A cumulative standard castration threshold (<50ng/ prostate cancer and for the treatment review of reported global cases dL; <1.7 nmol/L); and in most cases, of high risk localised and locally identified errors related to storage, patients reach testosterone levels advanced hormone dependent preparation and reconstitution of below <20ng/dL. prostate cancer in combination Eligard.
    [Show full text]
  • Forty-Sixth Annual MALTO Medicinal Chemistry & Pharmacognosy
    Forty-Sixth Annual MALTO Medicinal Chemistry & Pharmacognosy Meeting-in-Miniature May 20th – 22nd, 2019 Hosted by The Department of Pharmaceutical Sciences College of Pharmacy University of Tennessee Health Science Center, Memphis, TN A A O O M L M L T T 1 | Page 2019 MALTO Meeting At the University of Tennessee Health Science Center College of Pharmacy Table of Contents Page 2019 MALTO Contributors and Sponsors……………..………….……....4 2019 MALTO Executive Officers……………..……………..…………..…4 MALTO Board of Directors………………………………………..………5 MALTO 2019 Organizing Committee……………………………………..5 General Program…………………………………………………….……6-7 MALTO – A Brief History………………………………………………..8-9 A. Nelson Voldeng Memorial Lecture………………………...…….....10-11 Dr. Jeff Aubé, Fred Eshelman Distinguished Professor of Chemistry, The University of North Carolina Eshelman School of Pharmacy Biographical Information………………………………………..….11 Abstract………………………………………………………………12 History of The Robert A. Magarian Outstanding Podium Presentation Award ………………………..……………………………….…………13-15 History of The Thomas L. Lemke Outstanding Poster Presentation Award…………………………………………………………..… …….16-17 History of The Ronald F. Borne Outstanding Poster Presentation Award……………………………………………………………………18-19 Meeting Schedule for Monday, May 20th, 2019…………………….….…20 2 | Page Meeting Schedule for Tuesday, May 21st, 2019………………………20-26 Meeting Schedule for Wednesday, May 22nd, 2019…………………..27-28 Podium Presentation Abstracts………..……………………...………29-52 Poster Presentation Abstracts …………………..……….……………53-70 MALTO Primary Contacts………………………………………...….71-73
    [Show full text]
  • Utility of Monitoring Mycophenolic Acid in Solid Organ Transplant Patients
    Evidence Report/Technology Assessment Number 164 Utility of Monitoring Mycophenolic Acid in Solid Organ Transplant Patients Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. 290-02-0020 Task Order Leader: Parminder Raina, Ph.D. Director, McMaster University Evidence-based Practice Center Co-Principal Investigators: Mark Oremus, Ph.D. Johannes Zeidler, Ph.D., D.A.B.C.C. Authors: Mark Oremus, Ph.D. Johannes Zeidler, Ph.D., D.A.B.C.C. Mary H.H. Ensom, Pharm.D., F.A.S.H.P., F.C.C.P., F.C.S.H.P. Mina Matsuda-Abedini, M.D.C.M., F.R.C.P.C. Cynthia Balion, Ph.D., F.C.A.C.B. Lynda Booker, B.A. Carolyn Archer, M.Sc. Parminder Raina, Ph.D. AHRQ Publication No. 08-E006 February 2008 This report is based on research conducted by the McMaster University Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-02-0020). The findings and conclusions in this document are those of the author(s), who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help clinicians, employers, policymakers, and others make informed decisions about the provision of health care services.
    [Show full text]
  • Thesis Outline
    PHARMACOKINETICS, LIMITED SAMPLING STRATEGIES, AND PHARMACOGENETICS OF MYCOPHENOLIC ACID IN THORACIC TRANSPLANT RECIPIENTS by LILLIAN S.L. TING M.Sc., The University of British Columbia, 2005 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY in The Faculty of Graduate Studies (Pharmaceutical Sciences) THE UNIVERSITY OF BRITISH COLUMBIA (Vancouver) March, 2009. © Lillian S.L. Ting, 2009 ABSTRACT Mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil, is an immunosuppressive agent known to exhibit wide inter-patient pharmacokinetic variability. The metabolism and transport of MPA and the phenolic (MPAG) and acyl (AcMPAG) glucuronides are mediated by UDP-glucuronosyltransferases (UGTs) and multidrug resistance-associated protein 2 (MRP2/ABCC2), respectively. Increasing evidence supports monitoring MPA area-under-the-concentration-time-curve; however, it is impractical and costly to implement. The objectives of this clinical study were to characterize MPA pharmacokinetics, develop MPA limited sampling strategies for estimating MPA exposure, and assess contribution of UGT and ABCC2 genetics to MPA pharmacokinetics and clinical outcomes in thoracic transplant recipients. Seventy thoracic (36 lung, 34 heart) transplant recipients were recruited. Eleven blood samples were obtained over a 12-hour dosing period at steady state. Plasma concentrations of MPA, MPAG, AcMPAG, and free MPA were measured by a high performance liquid chromatography-ultraviolet detection method, and conventional dose- normalized pharmacokinetic parameters were determined via non-compartmental methods. Limited sampling strategies were developed in 64 subjects by stepwise multiple regression analysis using the index group data, and tested in the validation group to determine bias and precision. Genetic polymorphisms in UGT and ABCC2 were determined by sequencing and their contributions to pharmacokinetic variability were investigated in 68 thoracic transplant recipients using multivariate analysis.
    [Show full text]
  • Mycophenolic Acid) Delayed-Release Tablets, for Oral Use System Disease
    HIGHLIGHTS OF PRESCRIBING INFORMATION Blood Dyscrasias including Pure Red Cell Aplasia (PRCA): Monitor for These highlights do not include all the information needed to use neutropenia or anemia; consider treatment interruption or dose reduction. MYFORTIC safely and effectively. See full prescribing information for (5.7) MYFORTIC. Serious GI Tract Complications (gastrointestinal bleeding, perforations and ulcers): Administer with caution to patients with active digestive MYFORTIC® (mycophenolic acid) delayed-release tablets, for oral use system disease. (5.8) Initial U.S. Approval: 2004 Immunizations: Avoid live vaccines. (5.9) WARNING: EMBRYOFETAL TOXICITY, MALIGNANCIES, AND Patients with Hereditary Deficiency of Hypoxanthine-guanine SERIOUS INFECTIONS Phosphoribosyl-transferase (HGPRT): May cause exacerbation of disease symptoms; avoid use. (5.10) See full prescribing information for complete boxed warning ------------------------------ADVERSE REACTIONS------------------------------- Use during pregnancy is associated with increased risks of pregnancy loss and congenital malformations. Females of reproductive potential Most common adverse reactions (≥20%): anemia, leukopenia, constipation, must be counseled regarding pregnancy prevention and planning. nausea, diarrhea, vomiting, dyspepsia, urinary tract infection, CMV infection, (5.1, 8.1, 8.6) insomnia, and postoperative pain. (6.2) Increased risk of development of lymphoma and other malignancies, To report SUSPECTED ADVERSE REACTIONS, contact Novartis particularly of the skin,
    [Show full text]
  • Immunosuppressive Therapy DR
    OCTOBER 2017 Immunosuppressive Therapy DR. ANDREW MACKIN BVSc BVMS MVS DVSc FANZCVSc DipACVIM Professor of Small Animal Internal Medicine Mississippi State University College of Veterinary Medicine, Starkville, MS A number of established immunosuppressive agents have been used in small animal medicine for many decades. Some have justifiably fallen out of favor whereas, for others, new and promising uses have been described in the recent veterinary literature. Established “old favorites” have included cyclophosphamide, chlorambucil, azathioprine, danazol and vincristine, although cyclophosphamide and danazol are rarely used as immunosuppressive agents these days. Several potent immunosuppressive drugs developed over the past few decades in human medicine have recently made the leap to our small animal patients, and our use of drugs such as cyclosporine, leflunomide and mycophenolate is growing. Cyclophosphamide Cyclophosphamide, a cell-cycle nonspecific nitrogen mustard derivative alkylating agent, was one of the first major chemotherapeutic agents approved by the FDA over 50 years ago, and has since become very well-established in human medicine as both an antineoplastic drug and as an immunosuppressive agent. Within a few years of FDA approval in the late 1950s, the use of cyclophosphamide for the prevention of transplant rejection in experimental models and for the treatment of both neoplasia and immune-mediated diseases was described in both dogs and cats. Cyclophosphamide has persisted to this day as one of the core drugs used in many small animal cancer chemotherapeutic protocols. In contrast, after many years as one of the most commonly immunosuppressive drugs utilized to treat immune-mediated diseases in cats and dogs, the use of cyclophosphamide as an immunosuppressive agent in small animal patients has in the past two decades essentially faded away.
    [Show full text]
  • Drug Interactions in Stem Cell Transplantation
    Drug Interactions in Stem Cell Transplantation Jeannine McCune, PharmD, BCOP University of Washington Fred Hutchinson Cancer Research Center When is a drug interaction in HCT Learning Objectives recipients important? Explain the common metabolic pathways Drug interaction leads to an undesired in the liver outcome, whether it be efficacy or ↑ toxicity Identify approaches to overcome drug interactions seen in HSCT Type of interactions Pharmaceutical Identify those drug interactions of importance Pharmacokinetic Understand how to preemptively prevent drug Pharmacodynamic interactions from occurring The challenges unique to HCT Quick review of patients are ….. pharmacokinetic-based The concentration-effect (i.e., pharmacodynamic) relationships are drug interaction basics rarely defined Degree of an interaction (and thus its significance) rarely described Drug metabolizing enzymes Cytokines influence regulation Drug Transporters Interpatient variability in the interaction When an adverse drug interaction occurs, we often lack the pharmacokinetic data to explain it Relationship between Pharmacokinetics and Pharmacodynamics Rational Use of Drugs in Patients Dose What the body does to the drug – Absorption pharmacokinetics Distribution Metabolism Excretion Total serum concentration Receptor Site What the drug does to the body – pharmacodynamics Unbound serum concentration Pharmacologic Safety and efficacy Response Protein Bound Concentration Therapeutic Outcome Pharmacology is Multifactorial Pharmacokinetic Parameters Can affect
    [Show full text]
  • Mycophenolate Mofetil / Mycophenolic Acid
    Mycophenolate mofetil / Mycophenolic acid (U.S. only) pulmonaryfibrosis.org What are mycophenolate mofetil and mycophenolic acid? Mycophenolate mofetil (Cellcept®), abbreviated “MMF”, is a prescription medication that weakens the body’s immune system. The body naturally breaks down MMF into “mycophenolic acid” (abbreviated MPA), which is the active form of the drug. MPA (Myfortic®) is also available as a medication. Both drugs are FDA approved to treat patients who have undergone solid organ transplantation. They are also widely used “off label” to treat other conditions. How does MMF/MPA work? MMF and MPA both target the body’s white blood cells, slowing down their ability to multiply and respond to infection Who should take MMF/MPA? These medications should only be taken as instructed by your health care provider and according to the prescription label. It is commonly used to treat autoimmune diseases and certain forms of PF when inflammation is present in the lungs. How should MMF/MPA be taken? MMF comes in 250mg capsules and 500mg tablets. It is also available as an oral liquid (suspension) and as an intravenous infusion. MPA is available in 180mg and 720mg tablets. MMF and MPA doses are not interchangeable. MMF and MPA tablets should not be crushed, chewed, or cut prior to taking the medication. MMF capsules should not be opened or crushed before taking the medication. The FDA prescribing information states that MMF should be taken on an empty stomach. Some physicians recommend taking MMF with food. Talk to your health care provider for guidance. MMF should not be taken at the same time as antacids containing magnesium or aluminum.
    [Show full text]